Octagam (intravenous normal human immunoglobulin) / Octapharma  >>  Phase 3
Welcome,         Profile    Billing    Logout  

13 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Octagam (intravenous normal human immunoglobulin) / Octapharma
NCT00426270 / 2005-003552-35: Clinical Study to Evaluate the Efficacy and Safety of Octagam 10% in Idiopathic Thrombocytopenic Purpura in Adults

Completed
3
116
Europe
Octagam 10%, Human normal immunoglobulin
Octapharma
Immune Thrombocytopenic Purpura
09/08
09/08
NCT00430885: Effect of Intravenous Immunglobulin (IVIG) After Myocardial Infarction

Completed
3
62
Europe
Octagam (IVIG), Intravenous immunoglobulin 0.4 g/kg given as infusion
Oslo University Hospital, Helse Stavanger HF
Acute Myocardial Infarction
05/09
05/10
NCT00811174 / 2007-002611-27: Efficacy, Safety and Kinetics Study of Octagam 10% in Primary Immunodeficiency Diseases

Terminated
3
5
Europe
Octagam 10%
Octapharma
Immunologic Deficiency Syndromes
09/10
09/10
2012-000792-16: Study to evaluate the efficacy, metabolism and safety of human immune globulin in patients with primary immunodeficiency diseases

Completed
3
23
Europe
Octagam 5%, Solution for infusion, OCTAGAM 50 mg/ml oldatos infúzió
OCTAPHARMA AG, Octapharma AG
primary immunodeficiency disease (PID), lack of antibodies, Diseases [C] - Immune System Diseases [C20]
 
 
2012-000796-16: Study to evaluate the efficacy and safety of human immune globulin in patients with primary immune thrombocytopenia

Completed
3
30
Europe, RoW
Octagam 10%, Solution for infusion, Octagam 10%
OCTAPHARMA AG, Octapharma AG
Primary Immune Thrombocytopenia (ITP), immune mediated disorder characterized by increased platelet destruction, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2012-005086-12: Study to investigate the ability of a blood-derived score to select patients with relapsing multiple sclerosis who benefit from treatment with human immune globulin

Ongoing
3
81
Europe
Rebif 44 micrograms, Betaferon 250 microgram/ml, Extavia 250 microgram/ml, Octagam 50 mg/ml, Copaxone 20 mg/ml, Rebif 44 micrograms, Betaferon 250 microgram/ml, Extavia 250 microgram/ml, Octagam 50 mg/ml, Copaxone 20 mg/ml, Rebif 44 micrograms, Betaferon 250 microgram/ml, Extavia 250 microgram/ml
Octapharma AG, Octapharma AG
relapsing multiple sclerosis
 
 
ProDERM, NCT02728752 / 2016-002902-37: Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy)

Completed
3
95
Europe, Canada, US, RoW
Octagam 10%, Placebo
Octapharma
Dermatomyositis
11/19
11/19
2019-004433-17: Kawasaki Disease Coronary Artery Aneurysm Prevention trial

Ongoing
3
262
Europe
Prednisolone (Tablet 1mg), Prednisolone (Soluble Tablet 5mg), Prednisolone (Oral Solution 10mg/ml), Human Normal Immunoglobulin (IVIg 100mg/ml), Aspirin (Dispersible Tablet 75mg), Aspirin (Tablets 300mg), Prednisolone (Tablet 5mg), Prednisolone (Tablet 10mg), Prednisolone (Tablet 2.5mg), Prednisolone (Tablet 20mg), Prednisolone (Tablet 25mg), Prednisolone (Tablet 30mg), Methylprednisolone (500mg), Methylprednisolone (1000mg), Human Normal Immunoglobulin (IVIg 50mg/ml), Aspirin (Tablet 75mg), Methylprednisolone (40mg), Methylprednisolone (125mg), Methylprednisolone (2g), B01AC06, Tablet, Soluble tablet, Oral solution, Solution for injection/infusion, Dispersible tablet, Powder and solvent for solution for injection/infusion, Powder for injection, Asaflow (80mg), Aspirine (100mg), Aspegic 100mg, Cardioaspirine (100mg), Solu-Medrol S.A.B. (40mg), Octagam (50 mg/ml) solution for infusion, Octagam 10% solution for infusion, Privigen 100 mg/ml solution for infusion, Iqymune (100mg/mL), Okrido 6mg/ml drank
MRC CTU at UCL, Medical Research Council Clinical Trials Unit at University College London, UNIVERSITY COLLEGE LONDON, MRC Clinical Trials Unit at University College London (UCL), Innovative Medicines Initiative 2 Joint Undertaking, Innovative Medicines Initiative 2, Innovative Medicine Initiative 2 Joint Undertaking
Kawasaki Disease, Kawasaki Disease, Diseases [C] - Cardiovascular Diseases [C14]
 
 
NCT04400058 / 2020-002482-34: Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression

Completed
3
207
US, RoW
Octagam 10%, Saline Solution
Octapharma
Covid-19
02/22
02/22
IVIORDEX, NCT04968899: IgIV Plus Prednisone vs High-dose Dexamethasone for ITP

Recruiting
3
272
Europe
Neofordex®, Dexamethasone, Intravenous immunoglobulins, Tegeline®, Clayrig®,, Gammagard®,, Octagam®,, Privigen®,, Other IgIV patent medicine
Assistance Publique - Hôpitaux de Paris
Immune Thrombocytopenia (ITP)
04/25
10/26
NCT00545493: Efficacy of Tacrolimus and I.V.-Immunoglobulins in Rasmussen Encephalitis

Unknown status
2/3
16
Europe
Tacrolimus, Prograf, i.v. immunoglobulins, Octagam
University Hospital, Bonn, Octapharma, Astellas Pharma GmbH
Rasmussen Encephalitis
04/10
04/10
CAST, NCT03593902: Cardiac Safe Transplants for Systemic Sclerosis

Terminated
2/3
9
US
Rituximab, Rituxan, Fludarabine, Fludara, Cyclophosphamide, Cytoxan, Mesna, Mesnex, rATG, Thymoglobulin, Anti-Thymocyte Globulin (Rabbit), Methylprednisolone, Solu-Medrol, Depo-Medrol, G-CSF, Neupogen, Filgrastim, Granix, Zarxio, IVIg, Bivagam, Carimune NF, Gammagard, Privigen, Octagam, Autologous Stem Cells
Northwestern University
Systemic Sclerosis, Scleroderma
10/19
10/19
ATTEND, NCT03829566: Autologous Transplant To End NMO Spectrum Disorder

Withdrawn
2/3
0
US
Rituximab, Rituxan, Cyclophosphamide, Cytoxan, Mesna, Mesnex, rATG, Thymoglobulin, Anti-Thymocyte Globulin, Methylprednisolone, Solu-Medrol, Depo-Medrol, G-CSF, Neupogen, Filgrastim, Granix, Zarxio, IVIg, Bivigam, Carimune Nanofiltered (NF), Gammagard, Privigen, Octagam, Autologous Stem Cells
Northwestern University
Neuromyelitis Optica, Devic's Disease, NMO Spectrum Disorder
01/25
11/25

Download Options